الفهرس 
ContentOnly 14 pages are availabe for public view
 |  | from | 89 |  |  |
| | | from | 89 | | |
Abstract
It has been reported that chronic hepatitis B virus (HBV) infection has been known as one of the leading causes of cancer as well as liver failure worldwide. Preterm infants weighting <2000gm have been noticed to be at increased risk of a number of vaccine-preventable diseases including Hepatitis B because of exposure to biological products and hospital acquired infections during NICU stay. Antibody level of 10 mIU/ml was considered to serologically protect infant and give long-term protection. Aim of the work :This study aims to evaluate efficacy of hepatitis B vaccination seroconversion one month after first dose for preterm infants < 2000 gm given within 24hr of birth & infants will be protected if Anti-HBs equal to 10mIU/ml. Materials and Methods: 10μg /0.5ml of vaccine given IM in anterolateral aspect of right thigh within 24hr after birth. Infants carefully monitoried for apnea or cardiorespiratory compromise. Serum sample taken one month after first day dose of vaccine administration. HBsAb measured by chemiluminescent enzyme immunoassay (CLEIA). Results: The incidence of HB seroconversion among studied cases was 3.3%. there is no statistically significant association between incidence of seroconversion and gender, gestational age nor birth weight among studied cases. Conclusion: Hep B vaccination for preterms < 2kg born to Hep B negative mothers did not elicit sufficient antibody response when tested at 1 month. The vaccination didn’t induce immediate side effects.